RVLPQ (RVL Pharmaceuticals) Short-Term Debt: $57.75 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RVLPQ RVL Pharmaceuticals PLC RVLPQ
12 GF Score
Price $0.00
View Full Analysis

What is RVL Pharmaceuticals Short-Term Debt?

RVL Pharmaceuticals RVLPQ -90.00% 12 Short-Term Debt is $57.75 Mil as of Jun. 2023. GuruFocus rates RVLPQ with a GF Score™ of 12/100.

RVL Pharmaceuticals's Short-Term Debt for the quarter that ended in Jun. 2023 was $57.75 Mil.

RVL Pharmaceuticals's quarterly Short-Term Debt increased from Dec. 2022 ($1.43 Mil) to Mar. 2023 ($4.15 Mil) and increased from Mar. 2023 ($4.15 Mil) to Jun. 2023 ($57.75 Mil).

RVL Pharmaceuticals's annual Short-Term Debt increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($2.41 Mil) but then declined from Dec. 2021 ($2.41 Mil) to Dec. 2022 ($1.43 Mil).

RVL Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

RVL Pharmaceuticals Short-Term Debt Related Terms

RVL Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for RVL Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RVL Pharmaceuticals Short-Term Debt Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Short-Term Debt
Get a 7-Day Free Trial 1.77 0.00 0.00 2.41 1.43

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 0.00 1.43 4.15 57.75
RVLPQ
12GF Score
RVL Pharmaceuticals PLC RVLPQ
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $57.75 Mil mean?
RVL Pharmaceuticals (RVLPQ) has a Short-Term Debt of $57.75 Mil as of Jun. 2023.
Is RVL Pharmaceuticals' Short-Term Debt too high?
RVL Pharmaceuticals' current Short-Term Debt is $57.75 Mil. Overall, RVL Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RVL Pharmaceuticals' Short-Term Debt compare to SNPX and THAR?
RVL Pharmaceuticals' Short-Term Debt of $57.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. RVL Pharmaceuticals's current Short-Term Debt is $57.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RVL Pharmaceuticals stock overvalued right now?
RVL Pharmaceuticals (RVLPQ) has a current Short-Term Debt of $57.75 Mil. The current Short-Term Debt is $57.75 Mil. RVL Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For RVL Pharmaceuticals (RVLPQ), the current Short-Term Debt is $57.75 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RVL Pharmaceuticals Business Description

Address 400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
12GF Score

Get the complete analysis for RVLPQ

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price